BIVI · XBRL financial data

BioVie financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BIVI's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Research and development	133,188	17,258	33,300	23,100	9,267	13,962
Selling, general and administrative	4,637	9,765	11,552	8,850	8,570	—
General and administrative	—	—	—	—	8,570	8,511
Total operating expenses	138,054	27,253	45,080	32,180	18,066	22,652
Operating income (loss)	(138,054)	(27,253)	(45,080)	(32,180)	(18,066)	(22,652)
Interest expense	559	2,163	4,300	2,894	333	18
Net income (loss)	(130,249)	(26,084)	(50,256)	(32,121)	(17,542)	(22,073)
Earnings per share, basic USD per share	(14.82)	(1.06)	(1.55)	(7.30)	(12.12)	(3.05)
Earnings per share, diluted USD per share	(14.82)	(1.06)	(1.55)	(7.30)	(12.12)	(3.05)
Weighted average shares, basic thousands of shares	12,403	24,663	32,483	4,519	1,477	7,246
Weighted average shares, diluted thousands of shares	12,403	24,663	32,483	4,519	1,477	7,246

Fiscal years (BIVI's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	4,512	18,642	19,461	23,844	17,545	8,977
Prepaid and other current assets	—	—	—	204	1,050	—
Total current assets	4,605	18,780	34,041	24,048	20,698	13,642
Right-of-use asset	—	118	81	407	340	263
Goodwill	346	346	346	346	346	346
Total assets	6,047	20,115	35,105	25,208	21,562	14,250
Accounts payable	996	2,443	3,476	3,587	2,200	3,705
Total current liabilities	996	4,169	14,495	9,352	2,275	3,796
Lease liability, non-current	—	87	43	350	275	184
Total liabilities	996	16,444	19,764	9,702	2,550	3,980
Accumulated deficit	(224,885)	(250,970)	(301,226)	(334,233)	(352,144)	(374,261)
Total stockholders' equity	5,050	3,671	15,340	15,506	19,012	10,270
Total liabilities and equity	6,047	20,115	35,105	25,208	21,562	14,250
Common shares outstanding (cover page) thousands of shares	24,833	30,165	36,804	7,957	7,534	7,543

Fiscal years (BIVI's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	(130,249)	(26,084)	(50,256)	(32,121)	(17,542)	(22,073)
Stock-based compensation	3,020	5,808	4,223	2,824	1,195	2,284
Net cash from operating activities	(10,453)	(18,991)	(40,253)	(27,945)	(19,025)	(19,025)
Net cash from investing activities	—	—	(14,301)	14,525	—	—
Proceeds from issuing common stock	15,628	18,511	49,465	27,803	15,675	10,458
Net cash from financing activities	14,927	33,121	55,373	17,803	12,726	10,458

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Biovie	8,977	not reported	(4,122)*	7.5M	2.2 quarters	Q4 FY26 10-KJun 30, 2026
GT Biopharma	4,960	not reported	(4,260)*	45.1M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Talphera	742	not reported	(3,924)*	51.9M	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Processa Pharmaceuticals	196	not reported	(1,996)*	2.8M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
TherapeuticsMD	9,189	not reported	not reported	11.6M	—	Q2 FY26 10-QJun 30, 2026
Oncotelic Therapeutics	186	250	(92)*	457.5M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Artelo Biosciences	4,198	not reported	(5,033)*	4.6M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Orgenesis	78	301*	(2,098)*	9.8M	0.0 quarters	Q4 FY24 10-KDec 31, 2024

Not investment advice. Not affiliated with the U.S. SEC.